Table 3.
Effectiveness Primary-series Pneumococcal Conjugate Vaccine Doses Among Children Aged ≤12 Months
| Vaccine Exposure | Carriage Endpoint | Dosing Comparisons | ||||
|---|---|---|---|---|---|---|
| 1p ref. 0p | 2p ref. 0p | 1p ref. 2p | ||||
| mOR (95% CI) | VE (95% CI), % | mOR (95% CI) | VE (95% CI), % | mOR (95% CI) | ||
| PCV7/13 doses | PCV7 serotypes | 1.07 (.80–1.43) | −7 (−43 to 20) | 0.65 (.45–.92) | 35 (8–55) | 1.65 (1.16–2.35) |
| PCV13 doses only | All PCV13 serotypes | 0.86 (.64–1.13) | 14 (−13 to 36) | 0.47 (.63–.68) | 53 (32–67) | 1.83 (1.28–2.62) |
| +6PCV13 serotypes | 0.85 (.59–1.23) | 15 (−23 to 41) | 0.58 (.37–.93) | 42 (7–63) | 1.46 (1.03–2.16) | |
| PCV7 serotypes | 0.89 (.64–1.22) | 11 (−22 to 36) | 0.36 (.22–.57) | 64 (43–78) | 2.45 (1.50–4.05) | |
| PCV7 doses only | PCV7 serotypes | 1.23 (.74–2.11) | −23 (−111 to 26) | 1.00 (.59–1.72) | 0 (−72 to 41) | 1.24 (.74–2.05) |
Vaccine effectiveness estimates are calculated as 1-mOR times 100%. The mORs are calculated from the relative odds of receipt of each vaccination series among case children versus matched controls. Comparisons are structured as “1p ref. 0p”, “2p ref. 0p”, and “1p ref. 2p”. Here, “1p ref. 0p” and “2p ref. 0p” present the effectiveness of 1 and 2 primary doses, respectively, in comparison to 0 primary doses; “1p ref. 2p” presents the effectiveness of a single primary dose, in comparison to 2 primary doses.
Abbreviations: +6PCV13, the 6 serotypes contained in PCV13 and not PCV7; CI, confidence interval; mOR, matched odds ratio; p, primary dose; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; VE, vaccine effectiveness.